NEW YORK - Hoth Therapeutics , Inc. (NASDAQ:HOTH), a biopharmaceutical company focused on developing treatments for patients, announced today that it will maintain its partnership with Venable, LLP for intellectual property development and protection.
Venable, a Global 100 law firm recognized for its intellectual property expertise, will continue to provide strategic counsel to Hoth Therapeutics as the company advances its research and development efforts.
The collaboration aims to bolster Hoth Therapeutics' initiatives in creating innovative therapeutics. Robb Knie, CEO of Hoth Therapeutics, expressed confidence that Venable's support will enhance the value and protection of the company's expanding R&D portfolio. Jason Okun, a partner at Venable, also affirmed the firm's commitment to the ongoing partnership.
Hoth Therapeutics positions itself as a clinical-stage biopharmaceutical innovator, striving to improve patient quality of life through early-stage pharmaceutical research and development. The company works closely with scientists, clinicians, and key opinion leaders to identify and advance promising therapeutic candidates.
The press release also contains forward-looking statements regarding Hoth's business strategies, regulatory submissions, clinical trial timelines, and market acceptance of products, among other aspects. These statements are subject to risks, uncertainties, and assumptions and reflect the company's current expectations.
Investors are cautioned not to place undue reliance on these forward-looking statements, which are based on current plans, estimates, and beliefs of the company.
Hoth Therapeutics acknowledges that actual results may differ materially from those projected due to various important factors, including market conditions and risks detailed in the company's most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission.
This news is based on a press release statement from Hoth Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.